Related Experiment Videos
Development and characterization of an IL-4-secreting human ovarian carcinoma cell line
A D Santin1, G R Ioli, J C Hiserodt
1Department of Molecular Biology and Biochemistry, University of California, Irvine 92717, USA.
Abstract:
Human ovarian carcinoma cell lines were genetically engineered to secrete the cytokine interleukin-4 (IL-4) by retroviral-mediated gene transduction. These cells were transduced with the LXSN retroviral vector containing the human IL-4 gene and the neomycin resistance selection marker. Numerous IL-4-secreting clones were isolated from different papillary serous carcinoma cell lines, including SKOV-3, UCI-101, and UCI-107, and one clone derived from UCI-107 extensively characterized. This clone, termed UCI 107E IL-4 GS, was shown to constitutively express high levels of IL-4 (i.e., 900 to 1300 pg/ml/10(5) cells/48 hr) for over 35 passages and 6 months of study. Like the parental cell line (UCI-107), UCI 107E IL-4 GS cells expressed MHC class I and Her-2/neu surface antigens but did not express detectable MHC class II, ICAM 1, CA 125, or IL-4 receptors. No increase in expression of surface proteins was noted between parental and UCI 107E IL-4 GS. The morphology of this clone did not differ from that of the parental or LXSN vector control cells; however, parental cells had a faster growth rates than transductants. UCI 107E IL-4 GS was sensitive to gamma irradiation since as little as 2500 rad killed most of the cells within 10 days of irradiation. However, after irradiation, IL-4 secretion continued until about Day 8. The potential use of these IL-4-secreting ovarian carcinoma cells as vaccines for woman with advanced ovarian cancer will be discussed.
Insights
Genetically engineered ovarian cancer cells secrete interleukin-4 (IL-4), showing potential as a vaccine for advanced ovarian cancer. These modified cells maintain IL-4 secretion even after gamma irradiation.
Area of Science:
- Oncology
- Immunology
- Gene Therapy
Background:
- Ovarian carcinoma presents significant treatment challenges, particularly in advanced stages.
- Interleukin-4 (IL-4) is a cytokine with immunomodulatory properties that may influence anti-tumor responses.
- Developing novel therapeutic strategies, including cancer vaccines, is crucial for improving patient outcomes.
Purpose of the Study:
- To genetically engineer human ovarian carcinoma cell lines to secrete interleukin-4 (IL-4).
- To characterize the properties of these IL-4-secreting cells, including their stability, surface antigen expression, and response to irradiation.
- To evaluate the potential of these engineered cells as a vaccine for advanced ovarian cancer.
Main Methods:
- Retroviral-mediated gene transduction was used to introduce the human IL-4 gene into ovarian carcinoma cell lines (SKOV-3, UCI-101, UCI-107).
- Selected IL-4-secreting clones were isolated and characterized for IL-4 secretion levels, stability over passages, and expression of surface markers (MHC class I, Her-2/neu, MHC class II, ICAM 1, CA 125, IL-4 receptors).
- The engineered cells' response to gamma irradiation, including cell viability and continued IL-4 secretion, was assessed.
Main Results:
- Numerous IL-4-secreting clones were successfully generated from human ovarian carcinoma cell lines.
- One characterized clone (UCI 107E IL-4 GS) demonstrated stable, constitutive high-level IL-4 secretion for over 35 passages and 6 months.
- The engineered cells maintained expression of MHC class I and Her-2/neu but not MHC class II, ICAM 1, CA 125, or IL-4 receptors; their morphology was similar to parental cells, though growth rate was slower.
- UCI 107E IL-4 GS cells were sensitive to gamma irradiation, but IL-4 secretion persisted for approximately 8 days post-irradiation.
Conclusions:
- Genetically engineered ovarian carcinoma cells can be developed to stably secrete IL-4.
- These IL-4-secreting cells exhibit characteristics that warrant further investigation as a potential vaccine strategy for advanced ovarian cancer.
- The continued IL-4 secretion post-irradiation suggests a potential therapeutic window for this approach.